Thorsten Schinke Selected Research

MASS syndrome

11/2021	Transgenic inhibition of interleukin-6 trans-signaling does not prevent skeletal pathologies in mucolipidosis type II mice.
1/2019	Deficiency of sphingosine-1-phosphate receptor 3 does not affect the skeletal phenotype of mice lacking sphingosine-1-phosphate lyase.
1/2019	Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitis.
12/2006	Calcitonin deficiency in mice progressively results in high bone turnover.
2/2005	Increased bone formation in mice lacking apolipoprotein E.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thorsten Schinke Research Topics

Disease

18	Bone Resorption 01/2022 - 02/2005
16	Osteoporosis 01/2022 - 06/2009
7	Mucolipidoses (Sialidosis) 12/2021 - 12/2013
6	Familial Hypophosphatemic Rickets (X-Linked Hypophosphatemia) 01/2020 - 03/2013
5	Metabolic Bone Diseases (Osteopenia) 01/2022 - 12/2004
5	MASS syndrome 11/2021 - 02/2005
5	Neoplasm Metastasis (Metastasis) 01/2021 - 02/2010
4	Osteogenesis Imperfecta (Lobstein Disease) 01/2022 - 01/2017
4	Body Weight (Weight, Body) 01/2022 - 10/2010
4	Rickets (Rachitis) 01/2022 - 01/2020
4	Neoplasms (Cancer) 01/2021 - 02/2010
4	Obesity 01/2017 - 02/2004
3	Hypophosphatasia 01/2022 - 04/2008
3	Postmenopausal Osteoporosis 01/2022 - 01/2012
3	Osteolysis 01/2021 - 07/2007
3	Inflammation (Inflammations) 01/2019 - 01/2014
3	Osteopetrosis 01/2018 - 06/2009
3	Inborn Genetic Diseases (Disease, Hereditary) 01/2016 - 03/2013
2	Sepsis (Septicemia) 01/2022 - 01/2021
2	Hypophosphatemic Rickets 01/2022 - 01/2021
2	Osteomalacia 01/2022 - 01/2020
2	Osteosarcoma (Osteogenic Sarcoma) 01/2021 - 01/2015
2	Mucopolysaccharidoses 01/2020 - 04/2018
2	Mucopolysaccharidosis VI (Syndrome, Maroteaux-Lamy) 01/2020 - 12/2018
2	Metabolic Diseases (Metabolic Disease) 01/2020 - 01/2017
2	Hypophosphatemia 12/2018 - 10/2017
2	Vitamin D Deficiency 11/2018 - 01/2017
2	Bone Diseases (Bone Disease) 01/2017 - 01/2012
2	Wounds and Injuries (Trauma) 01/2017 - 01/2017
2	Secondary Hyperparathyroidism 11/2016 - 06/2009
2	Prostatic Neoplasms (Prostate Cancer) 04/2012 - 02/2010
1	Rare Diseases (Rare Disease) 01/2022
1	Primary Myelofibrosis (Myelosclerosis) 01/2022
1	Vascular Calcification 01/2022
1	Arterial calcification of infancy 01/2022
1	Osteitis Deformans (Paget's Disease of Bone) 01/2022
1	Arthritis (Polyarthritis) 01/2022
1	Osteosclerosis 01/2022
1	Pneumonia (Pneumonitis) 01/2021
1	Renal Insufficiency (Renal Failure) 01/2021
1	Endotoxemia 01/2021
1	Disease Progression 01/2021
1	Nephrocalcinosis 01/2021
1	Breast Neoplasms (Breast Cancer) 01/2021
1	Septic Shock (Toxic Shock Syndrome) 01/2021

Drug/Important Bio-Agent (IBA)

9	EnzymesIBA 01/2022 - 12/2015
7	Proteins (Proteins, Gene)FDA Link 01/2022 - 02/2004
6	CalciumIBA 01/2019 - 04/2014
5	Phosphates (Orthophosphate)IBA 01/2022 - 12/2013
5	Calcitonin Gene-Related PeptideIBA 09/2020 - 12/2004
4	Biomarkers (Surrogate Marker)IBA 01/2022 - 02/2017
4	GlycosaminoglycansIBA 01/2020 - 12/2015
4	Hormones (Hormone)IBA 01/2017 - 02/2004
4	LeptinIBA 01/2017 - 10/2010
3	Calcitonin Receptors (Calcitonin Receptor)IBA 01/2021 - 01/2017
3	Interleukin-17 (Interleukin 17)IBA 01/2021 - 03/2016
3	GlucocorticoidsIBA 01/2020 - 06/2010
3	Insulin (Novolin)FDA Link 01/2017 - 10/2010
3	Glucose (Dextrose)FDA LinkGeneric 01/2017 - 10/2010
3	Calcitonin (Calcitonin, Eel)FDA LinkGeneric 01/2017 - 12/2006
3	CateninsIBA 07/2015 - 01/2013
3	CytokinesIBA 12/2013 - 02/2010
3	Estrogens (Estrogen)FDA Link 01/2012 - 11/2010
2	ProcalcitoninIBA 01/2022 - 01/2021
2	ectonucleotide pyrophosphatase phosphodiesterase 1IBA 01/2022 - 01/2021
2	Fibroblast Growth Factor-23IBA 01/2022 - 12/2021
2	Phosphotransferases (Kinase)IBA 01/2022 - 01/2021
2	alpha2 Subunit Collagen Type IIBA 01/2022 - 11/2018
2	mutalipocin IIIBA 12/2021 - 01/2020
2	LigandsIBA 11/2021 - 05/2019
2	Interleukin-6 (Interleukin 6)IBA 11/2021 - 12/2013
2	ProteomeIBA 01/2021 - 01/2018
2	Alkaline PhosphataseIBA 01/2021 - 04/2008
2	NeuropeptidesIBA 09/2020 - 05/2008
2	Mannose (D-Mannose)IBA 01/2020 - 01/2016
2	MineralsIBA 01/2020 - 12/2018
2	N-Acetylgalactosamine-4-Sulfatase (Arylsulfatase B)IBA 01/2020 - 12/2018
2	ChemokinesIBA 01/2019 - 04/2012
2	CollagenIBA 01/2017 - 01/2016
2	alpha-2-HS-GlycoproteinIBA 01/2017 - 01/2012
2	EndopeptidasesIBA 12/2013 - 03/2013
2	Interleukin-33IBA 01/2012 - 04/2011
2	Apolipoproteins E (ApoE)IBA 10/2010 - 02/2005
1	Parathyroid Hormone (Parathormone)IBA 01/2022
1	NucleotidesIBA 01/2022
1	CB2 Cannabinoid ReceptorIBA 01/2022
1	1,25-dihydroxyvitamin DIBA 12/2021
1	Protein Isoforms (Isoforms)IBA 01/2021
1	Calcitonin Gene-Related Peptide Receptors (Calcitonin-Gene Related Peptide Receptor)IBA 01/2021
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2021
1	polypeptide 3 90kDa ribosomal protein S6 kinaseIBA 01/2021
1	N- (4'- fluorobutyrophenone)- 4- (4- chlorophenyl)pyridinium (HPP(+))IBA 01/2021
1	Calcitonin Gene-Related Peptide Receptor AntagonistsIBA 01/2021
1	olcegepantIBA 01/2021

Therapy/Procedure

6	Therapeutics 01/2021 - 06/2010
2	Ovariectomy (Oophorectomy) 01/2017 - 01/2016
2	Estrogen Replacement Therapy 01/2012 - 11/2010
1	Injections 01/2022
1	Ligation 01/2021
1	Punctures 01/2021